Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Magenta Therapeutics, Inc. (MGTA) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/19/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/03/2023 8-K Quarterly results
04/06/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
03/31/2023 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan"
02/07/2023 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Departure of Directors or Ce...
02/02/2023 8-K Quarterly results
01/25/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety"
12/20/2022 8-K Quarterly results
12/13/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
08/17/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights"
06/30/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/02/2022 8-K Quarterly results
04/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway"
03/08/2022 8-K Quarterly results
01/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022"
11/04/2021 8-K Quarterly results
Docs: "Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights",
"Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology Annual Meeting"
08/05/2021 8-K Quarterly results
07/27/2021 8-K Results of Operations and Financial Condition  Interactive Data
06/07/2021 8-K Quarterly results
05/27/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/03/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
12/23/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/09/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer CAMBRIDGE, Mass. - November 9, 2020 - Magenta Therapeutics , a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of Steve Mahoney as Chief Financial and Operating Officer. “We welcome Steve to Magenta as a seasoned biotech executive with a strong leadership background,” said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. “I look forward to partnering with Steve as we continue to grow Magenta and further establish our long-term clinical and commercial operations.” As Chief Financial and Operating Officer, Mr. Mahoney will serve as a member of the Company's Executi..."
11/05/2020 8-K Quarterly results
Docs: "Magenta Therapeutics Reports Recent Business Highlights and Third Quarter Financial Results"
10/02/2020 8-K Quarterly results
09/02/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
06/30/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy